SML0917
BMS-986122
≥98% (HPLC)
Sinônimo(s):
2-(3-Bromo-4-methoxyphenyl)-3-[(4-chlorophenyl)sulfonyl]-thiazolidine
Faça loginpara ver os preços organizacionais e de contrato
About This Item
Fórmula empírica (Notação de Hill):
C16H15BrClNO3S2
Número CAS:
Peso molecular:
448.78
Código UNSPSC:
12352200
NACRES:
NA.77
Produtos recomendados
Ensaio
≥98% (HPLC)
forma
powder
cor
white to beige
solubilidade
DMSO: 20 mg/mL, clear
temperatura de armazenamento
2-8°C
Ações bioquímicas/fisiológicas
BMS-986122 is a positive allosteric modulator (PAM of the m-opioid receptor). BMS986122 displays little or no agonist activity alone, but dose dependently increases endomorphin-I induced b-arrestin recruitment, and inhibition of forskolin-induced adenyl cyclase activity. The compound also potentiates DAMGO-stimulated GTPgS receptor binding.
BMS-986122 may exhibit an antinociception effect in vivo by increasing the efficiency of Met-enkephalin (met-Enk) to inhibit γ aminobutyric acid (GABA) release in the periaqueductal gray region of the brain.
Características e benefícios
This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
Palavra indicadora
Warning
Frases de perigo
Declarações de precaução
Classificações de perigo
Eye Irrit. 2
Código de classe de armazenamento
11 - Combustible Solids
Classe de risco de água (WGK)
WGK 3
Ponto de fulgor (°F)
Not applicable
Ponto de fulgor (°C)
Not applicable
Certificados de análise (COA)
Busque Certificados de análise (COA) digitando o Número do Lote do produto. Os números de lote e remessa podem ser encontrados no rótulo de um produto após a palavra “Lot” ou “Batch”.
Já possui este produto?
Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.
Ram Kandasamy et al.
Proceedings of the National Academy of Sciences of the United States of America, 118(16) (2021-04-14)
Positive allosteric modulators (PAMs) of the mu-opioid receptor (MOR) have been hypothesized as potentially safer analgesics than traditional opioid drugs. This is based on the idea that PAMs will promote the action of endogenous opioid peptides while preserving their temporal
Neil T Burford et al.
Proceedings of the National Academy of Sciences of the United States of America, 110(26), 10830-10835 (2013-06-12)
μ-Opioid receptors are among the most studied G protein-coupled receptors because of the therapeutic value of agonists, such as morphine, that are used to treat chronic pain. However, these drugs have significant side effects, such as respiratory suppression, constipation, allodynia
Kerri D Pryce et al.
Neuropharmacology, 195, 108673-108673 (2021-06-22)
Positive allosteric modulators (PAMs) of the μ-opioid receptor (MOR) have been proposed to exhibit therapeutic potential by maximizing the analgesic properties of clinically used opioid drugs while limiting their adverse effects or risk of overdose as a result of using
Artigos
DISCOVER Bioactive Small Molecules for Neuroscience
Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.
Entre em contato com a assistência técnica